Research Advances of metronomic Chemotherapy in Non-small Cell Lung Cancer

中国综合临床 Pub Date : 2020-03-01 DOI:10.3760/CMA.J.ISSN.1008-6315.2020.02.020

Yue Yu

引用次数: 0

Abstract

Advanced non-small cell lung cancer is one of the most difficult malignant tumors in the world. At present, chemotherapy is the most common treatment for NSCLC. However, traditional chemotherapy can kill tumor cells as well as normal cells. In order to solve this problem, metronomic chemotherapy came into being. It can inhibit tumor angiogenesis and tumor growth through a continuous high-frequency, low-dose administration. Metronomic chemotherapy can effectively control the disease progression of advanced NSCLC patients, delay their life span and improve their quality of life. Therefore, metronomic chemotherapy has become an effective treatment for advanced non-small cell lung cancer. Key words: Lung cancer; Metronomic Chemotherapy; Tumor

查看原文本刊更多论文

非小细胞肺癌癌症节拍化疗的研究进展

晚期癌症是世界上最难治疗的恶性肿瘤之一。目前，化疗是NSCLC最常见的治疗方法。然而，传统的化疗可以杀死肿瘤细胞和正常细胞。为了解决这个问题，节拍化疗应运而生。它可以通过连续的高频、低剂量给药来抑制肿瘤血管生成和肿瘤生长。节拍化疗可以有效控制晚期NSCLC患者的疾病进展，延缓其寿命，提高其生活质量。因此，节拍化疗已成为晚期癌症的有效治疗手段。关键词：肺癌癌症；节拍化疗；肿瘤

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国综合临床

CiteScore

0.10

自引率

0.00%

发文量

16855

期刊介绍： Clinical Medicine of China is an academic journal organized by the Chinese Medical Association (CMA), which mainly publishes original research papers, reviews and commentaries in the field. Clinical Medicine of China is a source journal of Peking University (2000 and 2004 editions), a core journal of Chinese science and technology, an academic journal of RCCSE China Core (Extended Edition), and has been published in Chemical Abstracts of the United States (CA), Abstracts Journal of Russia (AJ), Chinese Core Journals (Selection) Database, Chinese Science and Technology Materials Directory, Wanfang Database, China Academic Journal Database, JST Japan Science and Technology Agency Database (Japanese) (2018) and other databases.